COHANCE444.00

Cohance Lifesciences Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABSYNGENEASTERDMLALPATHLABNATCOPHARMWOCKPHARMANEULANDLABNHMcap ₹16,987 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
COHANCE
FY26
DIVISLAB
FY26
SYNGENE
FY26
ASTERDM
FY26
Peer
Median
Valuation — at last close
P/E94.67×97.31×48.79×101.99×97.31× -3%
P/B4.21×14.89×3.20×8.23×8.23× -49%
EV/EBITDA39.44×72.47×16.11×44.68×44.68× -12%
Market Cap₹16,987 Cr₹2.49L Cr₹15,471 Cr₹39,790 Cr₹39,790 Cr -57%
Growth
Revenue CAGR 3Y19.17%10.78%5.40%-26.99%5.40% +255%
Revenue CAGR 5Y17.57%8.67%11.35%-11.61%8.67% +103%
Net Income CAGR 3Y-28.53%12.09%-11.98%-3.51%-3.51% -713%
Revenue YoY (latest Q)-23.13%27.80%-15.84%21.60%21.60% -207%
Net Income YoY (latest Q)-197.39%65.50%-110.38%-68.70%-68.70% -187%
Profitability
EBITDA Margin18.82%32.59%24.57%19.41%24.57% -23%
Net Income Margin6.62%24.32%8.47%9.20%9.20% -28%
Return on Common Equity4.44%15.32%6.54%8.03%8.03% -45%
Return on Capital Employed4.71%16.55%8.46%8.93%8.93% -47%
Return on Assets2.62%12.82%4.49%5.27%5.27% -50%
Credit & Quality
Total Debt/Equity0.04×0.00×0.00×0.15×0.00×
Interest Coverage6.44×129.48×9.54×5.18×9.54× -32%
Scale — latest FY
Revenue / Total Income₹2,269 Cr₹10,560 Cr₹3,739 Cr₹4,643 Cr₹4,643 Cr -51%
Net Income₹150 Cr₹2,568 Cr₹317 Cr₹427 Cr₹427 Cr -65%
Total Assets₹5,730 Cr₹20,033 Cr₹7,055 Cr₹8,112 Cr₹8,112 Cr -29%
EPS₹4.69₹96.75₹7.87₹7.53₹7.87 -40%
Book Value per Share₹105.43₹632.49₹120.11₹93.29₹120.11 -12%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.